Heron Therapeutics, Inc. (HRTX)

NasdaqCM • Currently down 0.03 (-7.69%) in today's trading session

1 member of Congress has disclosed 1 trade in Heron Therapeutics, Inc. (HRTX) via STOCK Act filings. The most recent disclosure was a sale by Tom Malinowski on 18 May 2021. Aggregate disclosed activity totals roughly $32.5K in sales (midpoint estimates from bracketed disclosure amounts).

Heron Therapeutics, Inc. is currently trading at $0.36, positioned at 8% of its 52-week range ($0.26 – $1.58).

Want to automatically copy Pelosi trades?

Mirror Nancy Pelosi's portfolio with just one click on eToro.

Claim Free AssetCopy Automatically with eToro

Copy Trading does not amount to investment advice. The value of your investments may go up or down. Your capital is at risk.

Past Performance is not an indication of future results.

Current Price
$0.36
24h Change
-0.03 (-7.69%)
52 Week Range
$0.26–$1.58
View on NASDAQ

Heron Therapeutics, Inc. Price History and Technical Analysis

Interactive Chart

Congressional Trading Activity for HRTX

Select to highlight on chart
1 transactions
Compliance: 0%
Tom Malinowski18 May 202113 Aug 2022SaleStock$15,001 - $50,000N/A

Select transactions to view their annotations on the chart

Stock Overview

Market Data

Market Cap

$68.73M

Volume

2.09M

Beta

1.63

P/E Ratio

-2.78

Fundamentals

EPS

$-0.13

Div. Yield

-

Open

$0.38

Day Range

$0.36 – $0.40

Company Information

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ · USD
Country
US
CEO
Craig Alexander Collard
IPO Date
1987-08-26
Website
www.herontx.com

Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled r...

Earnings

Next Report

Q3 2026

3 Nov

EPS Est.

$-0.03

Rev. Est.

$37.5M

Days Until

19

Recent Quarters

Q2 202610 Aug
EPS$-0.03
Miss 500.0%
Q1 202611 May
EPS$-0.04
Miss 33.3%
Q4 202526 Feb
EPS$-0.02
Beat 33.3%
Q3 20254 Nov
EPS$-0.05
Miss 275.1%
Q2 20258 Aug
EPS$-0.02
Miss 100.0%
Q1 20256 May
EPS$0.01
Beat 200.0%
Q4 202427 Feb
EPS$0.02
Beat 166.7%
Q3 202412 Nov
EPS$-0.03
Miss 9.1%
Q2 20246 Aug
EPS$-0.06
Miss 50.0%
Q1 20247 May
EPS$-0.02
Beat 75.0%
Q4 202312 Mar
EPS$-0.07
Beat 53.3%
Q3 202314 Nov
EPS$-0.17
Beat 45.2%
Q2 202314 Aug
EPS$-0.35
Miss 52.2%
Q1 202311 May
EPS$-0.27
Miss 58.8%
Q4 202223 Mar
EPS$-0.17
Beat 32.0%
Q3 20228 Nov
EPS$-0.38
Beat 2.6%
Q2 20229 Aug
EPS$-0.55
Miss 10.0%
Q1 20229 May
EPS$-0.63
Miss 40.0%
Q4 202128 Feb
EPS$-0.54
Beat 8.5%
Q3 20213 Nov
EPS$-0.51
Beat 15.0%
Q2 20219 Aug
EPS$-0.62
Miss 5.1%
Q1 202110 May
EPS$-0.58
Miss 1.8%
Q4 202024 Feb
EPS$-0.68
Beat 0.0%
Q3 20205 Nov
EPS$-0.64
Beat 1.5%
Q2 20205 Aug
EPS$-0.61
Miss 3.4%
Q1 20206 May
EPS$-0.57
Beat 9.5%
Q4 20192 Mar
EPS$-0.65
Miss 12.1%
Q3 201912 Nov
EPS$-0.42
Beat 30.0%
Q2 20195 Aug
EPS$-0.63
Beat 7.3%
Q1 20199 May
EPS$-0.80
Miss 70.2%
Q4 201822 Feb
EPS$-0.63
Miss 37.0%
Q3 20187 Nov
EPS$-0.49
Miss 4.3%
Q2 20188 Aug
EPS$-0.54
Beat 21.7%
Q1 201810 May
EPS$-0.81
Beat 1.2%
Q4 201727 Feb
EPS$-0.97
Miss 24.4%
Q3 20176 Nov
EPS$-0.77
Beat 11.5%
Q2 20179 Aug
EPS$-0.80
Beat 15.8%
Q1 201710 May
EPS$-1.00
Miss 2.0%
Q4 201623 Feb
EPS$-1.03
Beat 8.8%
Q3 20168 Nov
EPS$-1.24
Miss 8.8%
Q2 20168 Aug
EPS$-1.17
Miss 21.9%
Q1 20165 May
EPS$-0.92
Beat 6.1%
Q4 201519 Feb
EPS$-0.87
Miss 35.9%
Q3 20156 Nov
EPS$-0.63
Beat 4.5%
Q2 20157 Aug
EPS$-0.74
Miss 19.4%
Q1 20158 May
EPS$-0.70
Miss 9.4%
Q4 201413 Mar
EPS$-0.71
Miss 2.9%
Q3 20146 Nov
EPS$-0.66
Beat 4.3%
Q2 20144 Aug
EPS$-0.78
Miss 25.8%
Q1 20148 May
EPS$-0.74
Miss 25.4%
Q4 20135 Mar
EPS$-0.75
Miss 7.1%
Q3 201312 Nov
EPS$-0.80
Beat 14.0%
Q2 20138 Aug
EPS$-1.00
Miss 25.0%
Q1 201310 May
EPS$-0.80
Miss 33.3%
Q4 20121 Mar
EPS$-0.60
Miss 50.0%
Q3 20125 Nov
EPS$-0.40
Miss 100.0%
Q2 20129 Aug
EPS$-0.46
Q2 20122 Aug
EPS$-0.40
Beat 0.0%
Q4 201126 Mar
EPS$-0.43
Q3 20117 Nov
EPS$-0.42
Q2 20118 Aug
EPS$-0.97
Q1 201116 May
EPS$-0.71
Q4 201026 Mar
EPS$-0.80
Q3 201015 Nov
EPS$-0.85
Q2 201016 Aug
EPS$-1.81
Q1 201017 May
EPS$-0.25
Q4 200913 Mar
EPS$-0.97
Q3 200916 Nov
EPS$-0.78
Q2 20094 Aug
EPS$-2.54
Q1 200914 May
EPS$-2.00
Beat 0.0%
Q4 200831 Mar
EPS$-2.60
Beat 36.6%
Q3 20085 Nov
EPS$-4.00
Beat 4.8%
Q2 200814 Aug
EPS$-4.00
Beat 9.1%
Q1 200815 May
EPS$-4.40
Miss 2.3%
Q4 200713 Mar
EPS$-5.00
Miss 42.9%
Q3 200713 Nov
EPS$-3.00
Beat 0.0%
Q2 200713 Aug
EPS$-3.70
Q2 20071 Aug
EPS$-3.80
Beat 70.3%
Q4 20067 Mar
EPS$-17.60
Miss 57.1%
Q3 20067 Nov
EPS$-48.32
Q1 200612 May
EPS$60.59
Q4 200531 Mar
EPS$-8.26
Q3 20059 Nov
EPS$-5.55
Q2 20058 Aug
EPS$-8.31
Q1 200510 May
EPS$-4.01
Q4 200414 Mar
EPS$-7.21
Q3 200415 Nov
EPS$-6.16
Q2 200413 Aug
EPS$-9.29
Q1 200414 May
EPS$-10.07
Q1 200428 Apr
EPS$-9.60
Miss 100.0%
Q3 200312 Nov
EPS$-4.11
Q2 200311 Aug
EPS$-7.64
Q1 200314 May
EPS$0.13
Q4 200228 Mar
EPS$-0.89
Q3 200220 Nov
EPS$-4.12
Q2 20028 Aug
EPS$-5.85
Q1 200214 May
EPS$-15.80
Q1 20027 May
EPS$-6.63
Q3 200113 Nov
EPS$5.88
Q2 200114 Aug
EPS$-4.72
Q1 200115 May
EPS$-4.44
Q4 200026 Mar
EPS$-6.30
Q3 20003 Nov
EPS$-2.40
Beat 50.0%
Q2 200015 Aug
EPS$-4.00
Miss 350.0%
Q1 200015 May
EPS$3.49
Q3 199911 Nov
EPS$2.40
Beat 50.0%
Q2 199929 Jul
EPS$1.60
Miss 63.6%
Q1 19996 May
EPS$1.60
Miss 71.4%
Q4 19984 Mar
EPS$4.80
Miss 33.3%
Q3 19984 Nov
EPS$2.40
Miss 50.0%
Q2 199812 Aug
EPS$0.80
Q2 199830 Jul
EPS$0.80
Q4 199730 Mar
EPS$-0.40
Q3 199712 Nov
EPS$-1.67
Q2 199712 Aug
EPS$-2.56
Q1 199714 May
EPS$1.74
Q4 199628 Mar
EPS$-13.90
Q3 199614 Nov
EPS$-9.20
Q2 199613 Aug
EPS$-9.48
Q1 199615 May
EPS$-9.22
Q4 199527 Mar
EPS$-20.74
Q3 199514 Nov
EPS$-9.77
Q2 199511 Aug
EPS$-9.72
Q1 199512 May
EPS$-4.45
Q3 199431 Dec
EPS$-13.56
Q2 199430 Sept
EPS$-14.64
Q1 199430 Jun
EPS$-14.03
Q4 199331 Mar
EPS$-10.22
Q3 199331 Dec
EPS$-18.18
Q2 199330 Sept
EPS$-14.66
Q1 199330 Jun
EPS$-16.63
Q4 199231 Mar
EPS$-10.71
Q3 199231 Dec
EPS$-11.17
Q2 199230 Sept
EPS$-5.58
Q1 199230 Jun
EPS$-6.41
Q4 199131 Mar
EPS$-12.55
Q3 199131 Dec
EPS$-12.25
Q2 199130 Sept
EPS$-9.80
Q1 199130 Jun
EPS$-4.09
Q4 199031 Mar
EPS$-9.06
Q3 199031 Dec
EPS$-4.94
Q2 199030 Sept
EPS$-9.89
Q1 199030 Jun
EPS$-9.07
Q4 198931 Mar
EPS$-7.55
Q3 198931 Dec
EPS$-9.26
Q2 198930 Sept
EPS$-7.57
Q1 198930 Jun
EPS$-7.57
Q4 198831 Mar
EPS$-51.20
Q3 198831 Dec
EPS$-11.00
Q2 198830 Sept
EPS$-51.20
Q1 198830 Jun
EPS$-38.40
Q4 198731 Mar
EPS$-19.20
Q3 198731 Dec
EPS$-8.77
Q2 198730 Sept
EPS$-51.20
Q1 198730 Jun
EPS$-44.80
Q4 198631 Mar
EPS$-44.80

No dividend data available for this stock.

Stock Splits

Split History

13 Jan 2014Reverse Split
Ratio1:20
25 May 2007Reverse Split
Ratio1:4

Similar Stocks

Based on congressional trading patterns

Smart Recommendations
No similar stocks found
No congressional trading patterns available for recommendations

Frequently Asked Questions about HRTX

Which members of Congress have traded HRTX?
1 member of Congress has disclosed 1 trade in Heron Therapeutics, Inc. (HRTX) under the STOCK Act: Tom Malinowski.
When was HRTX most recently disclosed by Congress?
The most recent HRTX disclosure was a sale by Tom Malinowski on 18 May 2021.
What is the total disclosed congressional trading volume for HRTX?
Members of Congress have disclosed approximately $32.5K in HRTX sales (midpoint estimate derived from the bracketed amount ranges used in STOCK Act filings).
How can I track new congressional trades in HRTX?
This HRTX page updates as soon as new STOCK Act disclosures are filed for Heron Therapeutics, Inc.. Every trade, politician, transaction date and amount range is surfaced above, typically within hours of the official filing appearing on the House or Senate disclosure portals.
Pelosi Tracker
PoliticiansBillsArticlesPortfoliosPricingAboutLegalTerms of ServicePrivacy Policy
Français
© 2026 - All rights reserved. Powered by Vantara Labs
Pelosi Tracker is an independent, third-party platform. It is not affiliated with, endorsed by, or in any way associated with Nancy Pelosi, her office or her representatives, or with any other member of Congress. Any use of her name is solely for the purpose of discussing publicly available information.The information provided by Pelosi Tracker is for informational and educational purposes only and is not intended to serve as, nor should it be construed as, financial or investment advice. The data presented here is sourced from publicly available filings and records. While we strive for accuracy, timeliness, and completeness, we do not guarantee that all information is error-free or current.